Navigation Links
Soligenix Announces Formation of Pediatric Crohn's Disease Medical Advisory Board
Date:10/11/2011

e subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, SGX202, SGX203, RiVax™, and LPM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the DSMB's recent determination disclosed in our Form 8-K dated September 15, 2011 recommending that Soligenix stop its confirmatory Phase 3 clinical trial of orBec® in acute GI GVHD and  the risk that: the FDA will  require that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec®
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (NYSE: RMD ), an innovator and pioneer ... and other chronic respiratory conditions, has won a permanent ... medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales ... 220 masks.  The judgment was entered by the Regional ... appealable, and applies throughout Germany.  The ...
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... plans to release its second quarter and year-to-date 2014 ... opening of the U.S. financial markets. The earnings press ... of the Company,s website, www.anipharmaceuticals.com . ... Officer, and Charlotte C. Arnold , Vice President ...
(Date:7/28/2014)... , July 28, 2014  ProteinSimple announced today ... the Simple Western. This new assay allows users to detect ... first time, Simple Western users can analyze proteins without ... Simple Western has changed protein analysis as we know ... Western blot protocols - no messy gels, no transfer ...
Breaking Medicine Technology:ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2ProteinSimple Says "Never Run a Gel Again!" 2
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today ... of Lenocta(TM) (sodium stibogluconate), a novel,protein tyrosine ... immune stimulant approved for the treatment of ... cancers. The open-label Phase IIa study is,designed ...
... CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical ... Exchange: TOPO) announced,today that updated preliminary clinical trial ... T-cell lymphomas, and new preclinical data,evaluating belinostat on ... 2007 American Society of Hematology (ASH) 49th Annual ...
Cached Medicine Technology:VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 2VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 3VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 An estimated ... year from metastatic breast and prostate cancers – an ... cancer has spread to other parts of the body, ... researchers at Drexel University College of Medicine ... identified that inhibits metastatic progression by blocking tumor cells ...
(Date:7/28/2014)... A revised version of a surgical procedure to treat ... more than 90 percent of the time in patients ... the MGH Division of Plastic and Reconstructive Surgery report ... the non-endoscopic procedure all of whom had headaches ... symptom relief a year later. The team,s paper ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... (HealthDay News) --,The more chronic medical conditions people have ... be, a new study claims. Since nearly ... scientists at Johns Hopkins Bloomberg School of Public Health ... gains in life expectancy are slowing in the United ... diabetes, kidney disease and heart failure is now the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2
... as the newest participants in the Hartford Doctoral Fellows ... by the John A. Hartford Foundation , administered by ... James Lubben , DSW, MPH. Each fellow receives ... his or her home institution, which enables the recipient to ...
... , FRIDAY, Oct. 28 (HealthDay News) -- ... improvement if they,re placed in a classroom with higher-achieving ... low-achievers, researchers say. The findings are important because ... to poor children, whose development of language skills may ...
... recently awarded $7.2 million for the competitive renewal of ... Cancer Center,s Daniel Sullivan, M.D., executive vice president and ... through September 2016. The SEP2C enrolls patients to ... across six member sites. Moffitt is the lead site ...
... shrinking population of trim Americans against an expanding population of ... "fat bans." These "fat policies" would be designed to ... the growth in Americans, waistlines and in the country,s healthcare ... the Land of the Free and the Home of ...
... takes advantage of ovarian cancer,s reliance on folate appears to ... effects, researchers say., The therapy uses the folate receptors on ... a substance attracted to the receptors with a chemotherapeutic agent ... Chief of the Section of Gynecologic Oncology at Georgia Health ...
... burn up to 120 calories in half an hour while wheeling ... as much as someone doing the same action in a motorized ... and as much as 258 calories while fencing in a 30-minute ... This is according to a review article written by Professor David ...
Cached Medicine News:Health News:Prestigious Hartford grants bolster awardees' social work research 2Health News:Prestigious Hartford grants bolster awardees' social work research 3Health News:Preschool Peers May Boost Language Skills in Kids 2Health News:Home of the free - land of the fat? 2Health News:Folate receptors may serve as a front door to ovarian cancer treatment 2Health News:UT study looks at manual wheelchair use, exercise and calorie burning 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: